RegenerativeTreatment Guide
  • Conditions
  • Locations
  • How It Works
  • About
  • Blog
  • For Providers
  • Cost Calculator
  • Free Assessment
(888) 540-7505
  1. Home
  2. Blog
  3. Does Medicare Cover Stem Cell Therapy or PRP?
Insurance & Coverage

Does Medicare Cover Stem Cell Therapy or PRP?

What traditional Medicare, Medicare Advantage, and the three Medicare contractor regions with explicit non-coverage policies actually say — straight from the CMS Coverage Database.

Insurance  ·  By the Regenerative Treatment Guide Editorial Team  ·  Published November 2, 2026  ·  9 min read

The short answer

No. Medicare does not cover stem cell therapy or PRP for joints, back pain, or any orthopedic use. PRP is covered only for chronic non-healing diabetic wounds, under national coverage determination NCD 270.3. Three Medicare Administrative Contractor (MAC) regions — covering at least 11 states and two U.S. territories — have published explicit local coverage determinations declaring musculoskeletal PRP "not medically reasonable and necessary." There is no national or local coverage determination for mesenchymal stem cell or bone marrow aspirate concentrate (BMAC) injections for orthopedic use; those claims are reviewed under general reasonable-and-necessary rules and consistently denied as investigational.

Medicare does cover FDA-approved stem-cell products for their approved indications — such as hematopoietic cord-blood transplants and the pediatric aGVHD drug Ryoncil — but these are hospital-administered treatments, not the joint injections sold by regenerative clinics.

Insurance coverage is one of the most-asked questions about regenerative medicine, and the Medicare answer is more concrete than people expect. Unlike commercial insurers' general "experimental" language, Medicare has specific, dated, searchable documents in the CMS Coverage Database that spell out exactly what is and isn't covered. This page summarizes those documents and links each one directly.

Does Medicare cover PRP?

Yes, but only in one narrow situation. The single Medicare national coverage determination (NCD) for platelet-rich plasma is NCD 270.3, Blood-Derived Products for Chronic Non-Healing Wounds (effective April 13, 2021). It covers autologous PRP for chronic non-healing diabetic wounds, for up to 20 weeks under a CMS-approved coverage with evidence development (CED) framework, using HCPCS code G0465. Beyond 20 weeks and for non-diabetic chronic wounds, coverage is left to local Medicare Administrative Contractors (code G0460).

Every other PRP indication — knee or shoulder osteoarthritis, rotator cuff, Achilles tendinopathy, chronic low back pain, hair loss, aesthetic treatments — falls outside NCD 270.3. In practice, that means Medicare does not pay for it anywhere in the country.

Three MAC regions explicitly non-cover PRP for joints

Three Medicare Administrative Contractors have gone further and published formal local coverage determinations (LCDs) that explicitly non-cover PRP for musculoskeletal use. Together they define coverage for roughly 11 states plus two territories, and they're the clearest written statement of Medicare's position:

LCDContractorStates / territoriesWhat it says
L39023 CGS Administrators (MAC J15) Kentucky, Ohio "Non-coverage policy for all Platelet Rich Plasma injections" for musculoskeletal injuries and joint conditions. Explicitly extends non-coverage to PRP combined with stem cells. Original effective Jan 3, 2022; last revised Feb 14, 2025.
L39071 First Coast Service Options Florida, Puerto Rico, U.S. Virgin Islands "Platelet rich plasma injections and/or applications are considered not medically reasonable and necessary." Also addresses PRP combined with stem cells for MSK and joint use. Effective Dec 12, 2021.
L38745 Palmetto GBA Alabama, Georgia, Tennessee, South Carolina, Virginia, West Virginia, North Carolina "NON-coverage LCD for all platelet-rich plasma (PRP) injections and/or applications" for muscle, bone, or joint use. Original effective Feb 7, 2021; last revised Mar 13, 2025.

In the remaining states and territories, there is no explicit non-coverage LCD, but PRP for joints is still reviewed under general Social Security Act §1862(a)(1)(A) "reasonable and necessary" rules — and claims are consistently denied for the same reasons the three MACs above spelled out in writing.

Does Medicare cover stem cell therapy for joints?

No. There is no Medicare national coverage determination for mesenchymal stem cell (MSC), bone marrow aspirate concentrate (BMAC), adipose-derived stem cell, or umbilical cord stem cell injections for orthopedic use. There are also no local coverage determinations that specifically address stem cell injections for joints by name — only the CGS LCD above, which non-covers PRP combined with stem cells.

That doesn't mean they're a gray area. In the absence of a coverage determination, claims are reviewed under general reasonable-and-necessary rules, and Medicare contractors consistently deny stem cell orthopedic claims as investigational — the same way commercial insurers do. No stem cell product has FDA approval for a joint, tendon, or spine indication, which is the policy anchor insurers point to.

Does Medicare cover stem cell therapy for shoulders?

No. Medicare does not cover stem cell injections for the shoulder, including the rotator cuff and labrum. The same rules apply as for every other joint: no stem cell product is FDA-approved for a shoulder condition, so claims are denied as investigational. PRP for the rotator cuff or shoulder arthritis also falls outside Medicare's one PRP coverage policy (see above). For what shoulder treatments cost out of pocket, see our rotator cuff cost estimate.

What Medicare does cover

The "stem cell" category includes several FDA-approved treatments that are entirely separate from the regenerative clinic market. These are covered when billed for their approved indications:

  • Hematopoietic stem cell transplants (bone marrow or cord blood) for leukemia, lymphoma, sickle cell disease, and certain other blood disorders. These are inpatient hospital procedures with decades of clinical use.
  • Ryoncil (remestemcel-L-rknd) — the first FDA-approved mesenchymal stem cell product, approved December 18, 2024 for pediatric steroid-refractory acute graft-versus-host disease in children two months and older. Medicare billing code HCPCS J3402 became active October 1, 2025. It is a hospital-administered pediatric transplant drug — nothing to do with joint injection clinics.

If a clinic implies that these approvals somehow mean "stem cells are FDA-approved" or hints that Medicare pays for stem cell injections, that is a sales technique, not a correct reading of the policy. See is stem cell therapy FDA-approved? for the full breakdown.

What about Medicare Advantage?

Medicare Advantage (Part C) plans are required to cover at least what traditional Medicare covers, and they cannot be more restrictive on medical necessity. Because traditional Medicare does not cover stem cell or PRP injections for joints, Medicare Advantage plans do not either.

A small number of Advantage plans offer limited supplemental benefits that may include some regenerative-adjacent services (acupuncture, chiropractic, over-the-counter supplements). Those are plan-specific and almost never cover a stem cell injection. If you have a Medicare Advantage plan, call the member services number on your card before scheduling anything — don't rely on what a clinic says the plan covers.

Private insurance follows the same logic

The major commercial insurers all land in the same place as Medicare, for the same reason — no FDA approval for orthopedic indications. Representative policy language:

  • UnitedHealthcare's Autologous Cellular Therapy medical policy classifies autologous stem cell therapy as unproven and not medically necessary for all indications.
  • Aetna classifies bone marrow aspirate concentrate and mesenchymal stem cell therapy for orthopedic use (including osteoarthritis) as experimental and investigational.
  • Cigna considers stem cell therapy for orthopedic conditions not medically necessary.
  • Blue Cross plans that follow the national Blue Cross Blue Shield Association medical policy classify it as investigational.

Your own plan document has the final word. Policies are revised periodically — always confirm the current version before counting on any coverage.

So what do people actually pay?

Because Medicare and private insurance both decline, stem cell therapy is almost entirely a cash-pay market. Published U.S. price surveys for knee injections found averages of $2,728 to $5,156 per injection, with the full range of quotes running from $300 to $12,000. For the complete price breakdown — surveys, cost by joint, financing — see how much does stem cell therapy cost? For the knee specifically, see stem cell knee injection cost: what 4 price studies found.

Frequently asked questions

No, not for orthopedic or anti-aging use. Medicare has no national or local coverage determination for mesenchymal stem cell or bone marrow aspirate concentrate (BMAC) injections for joints, spine, or tendons, and these claims are consistently denied as investigational. Medicare does cover FDA-approved stem-cell products for their approved indications, such as hematopoietic cord-blood transplants for blood disorders and Ryoncil for pediatric steroid-refractory acute graft-versus-host disease — but these are hospital-administered treatments, not the joint injections sold by regenerative clinics.
Only for chronic non-healing diabetic wounds, and only under a specific national coverage policy (NCD 270.3). PRP for joints, tendons, back pain, or any other musculoskeletal use is not covered. Three Medicare Administrative Contractor regions — covering at least 11 states and two U.S. territories — have published explicit local coverage determinations declaring PRP for musculoskeletal use not reasonable and necessary.
As of 2026, three Medicare Administrative Contractors have published non-coverage LCDs for musculoskeletal PRP: CGS Administrators (L39023, covering Kentucky and Ohio), First Coast Service Options (L39071, covering Florida, Puerto Rico, and the U.S. Virgin Islands), and Palmetto GBA (L38745, covering Alabama, Georgia, Tennessee, South Carolina, Virginia, West Virginia, and North Carolina). The CGS LCD explicitly extends non-coverage to PRP combined with stem cells. In the remaining states, PRP for joints is reviewed under general reasonable-and-necessary rules and is consistently denied.
Medicare Advantage plans are required to cover at least what traditional Medicare covers and cannot be more restrictive on medical necessity. Because traditional Medicare does not cover stem cell or PRP injections for joints, Medicare Advantage plans also do not. Some plans may offer limited supplemental benefits — call the plan directly before scheduling anything.
They all follow the same logic as Medicare. UnitedHealthcare's Autologous Cellular Therapy medical policy classifies autologous stem cell therapy as unproven and not medically necessary for all indications. Aetna classifies BMAC and mesenchymal stem cell therapy for orthopedic use as experimental and investigational. Cigna considers stem cell therapy for orthopedic conditions not medically necessary. Blue Cross plans that follow the national Blue Cross Blue Shield Association policy classify it as investigational. Expect to pay out of pocket.
Medicare covers treatments it considers reasonable and necessary based on published evidence. Total knee replacement has decades of clinical data showing durable improvement in pain and function. Stem cell injections for knee osteoarthritis do have evidence — a 2021 meta-analysis of nine randomized controlled trials found pain and function improvements lasting up to two years — but the trials are small and heterogeneous, and no stem cell product has FDA approval for orthopedic use. That gap is why insurers call it investigational, regardless of what individual patients experience.

Get a cost range for your situation

Since insurance won't cover it, knowing the cash price up front matters. Answer a few questions about your condition and location for a personalized estimate — free, no obligation.

Open the Cost Calculator

Get matched with a clinic and a clear quote

Take a quick assessment and we'll connect you with a verified clinic that can walk you through pricing and financing.

Take the Free Assessment

Related reading

  • How Much Does Stem Cell Therapy Cost?
  • Stem Cell Knee Injection Cost: What 4 Price Studies Found
  • PRP Knee Injection Cost: What 5 U.S. Studies Found
  • Is Stem Cell Therapy FDA Approved? Safety & Risks
  • FDA Warning Letters to Stem Cell Clinics
  • What the Research Actually Shows
This article is for educational purposes only and is not medical, legal, or financial advice. Medicare and insurance coverage policies are updated periodically; always confirm current coverage with Medicare, your plan administrator, and your provider before scheduling treatment. Policy references above link directly to the CMS Coverage Database and FDA source documents.

Medical Disclaimer

The information provided on this website is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Stem cell therapy results vary by patient and are not guaranteed. Stem cell therapy is not FDA-approved for all conditions. Always consult with a qualified healthcare provider to discuss your specific medical situation and treatment options.


© 2026 Regenerative Treatment Guide. All rights reserved.

Talk to a clinic: (888) 540-7505 · Mon–Sat 8am–6pm ET

  • About Us
  • Regenerative Medicine for Dogs
  • Blog
  • For Providers
  • Approved Providers
  • Podcast
  • FDA & Safety
  • FDA Warning Letters
  • Cost Calculator
  • Privacy Policy
  • Terms of Service
  • Medical Disclaimer
  • Facebook
  • YouTube
  • LinkedIn